Why is Ellume hitting headlines today?

Brisbane-based diagnostics developer Ellume is back in the headlines.

Rapid Antigen Test taking place.

Image source: Getty iMAGES

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Key points

  • Ellume is in the spotlight as the United States Government looks to buy another 500 million RATs
  • Additionally, the company has reportedly started working to get approval to sell its tests in Australia
  • There's still no word of Ellume listing on the ASX

Brisbane-based diagnostics developer Ellume is back in the headlines as demand for rapid antigen tests (RATs) continues to hit Australia and the world.

However – while there has been speculation – there's been no word as to whether we'll see shares in the company on our home-spun market.

Ellume isn't listed on the ASX. In fact, there's still nowhere for investors to publicly buy shares in the company.

Let's take a closer look at what's got many excited about the company this morning.

What's got ASX-watchers excited about Ellume on Friday?

The first news that might have put the spotlight on Ellume this morning came from its major market, the United States.

While most Australians slept last night, President Joe Biden announced that the United States Government will be handing out 1 billion free tests to citizens – 500 million more than previously promised. That means the government will be off to the shops looking to snap up the extra RATs.

Ellume's test was the first over the counter at-home RAT to be approved by the country's Food and Drug Administration back in December 2020. Since then, the United States Government has snapped up millions of them.

That likely leaves many wondering if its products could once again be in the government's cart.  

Back home, the ABC today reported it understands that Ellume has begun the journey of receiving Therapeutic Goods Administration (TGA) approval for its RAT tests.

If given the green light by the regulator, the tests will be allowed to be purchased by Australian consumers. Though, that doesn't mean they'll be on shelves any time soon.

Previously, Brisbane Times reported, while Ellume planned to submit its product for TGA approval early this year, the company stated it can't supply Australia with RATs until mid-2022.

However, the scramble for RATs that has likely put focus on Ellume also seems to have boosted the share price of its ASX-listed peers.

Right now, the AnteoTech Ltd (ASX: ADO) share price is up 3.92%. Meanwhile, that of Lumos Diagnostic Holdings Ltd (ASX: LDX) has gained 2.5%. Both companies are selling their RATs overseas while they await TGA clearance.

Motley Fool contributor Brooke Cooper has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

More on Share Market News

Young lady in JB Hi-Fi electronics store checking out laptops for sale
Broker Notes

Up 75% in a year, should you buy JB Hi-Fi shares ahead of next week's earnings result?

Macquarie reveals its outlook for JB Hi-Fi shares ahead of next week’s earnings results.

Read more »

A few gold nullets sit on an old-fashioned gold scale, representing ASX gold shares.
Broker Notes

Macquarie predicts 18% upside for this ASX gold mining stock

Here's what the broker thinks of the gold mining stock.

Read more »

A man sitting at his dining table looks at his laptop and ponders the CSL balance sheet and the value of CSL shares today
Broker Notes

Brokers name 3 ASX shares to buy today

Here's why brokers are feeling bullish about these three shares this week.

Read more »

Smiling couple sitting on a couch with laptops fist pump each other.
Share Gainers

Why Block, Iress, Nick Scali, and Westgold shares are storming higher today

These shares are ending the week with a bang. But why?

Read more »

Person with thumbs down and a red sad face poster covering the face.
Share Fallers

Why Clarity Pharmaceuticals, GQG Partners, Light & Wonder, and QBE shares are dropping today

These shares are ending the week in the red. But why?

Read more »

Shot of a young scientist looking stressed out while working on a computer in a lab.
Healthcare Shares

Guess which ASX All Ords stock just crashed 23% on earnings miss

Investors are sending the ASX All Ords stock tumbling on Friday. But why?

Read more »

A man wearing a blue jumper and a hat looks at his laptop with a distressed and fearful look on his face.
Broker Notes

How much upside does Macquarie see for AMP shares after its result?

The company released its H1 2025 results on Thursday.

Read more »

Miner looking at his notes.
Industrials Shares

Forget BHP, this little known gem is roaring 30% in FY 2026

This little-known services company is quietly capitalising on mining and infrastructure activity across nine countries, and investors are starting to…

Read more »